A New Way of Healing
SPRAVATO® Therapy in Boston, MA
If you have lived with depression that hasn’t responded to antidepressants, SPRAVATO® (esketamine) may offer a path forward. At Cambridge Biotherapies™, we provide SPRAVATO® treatment to Boston patients in a REMS-certified outpatient healthcare setting just minutes from downtown Boston. SPRAVATO® is FDA-approved, in conjunction with an oral antidepressant, for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It is administered under direct medical supervision by our team, led by Harvard-trained Medical Director Dr. Daniel A. Brenner, a board-certified psychiatrist.
If you are in crisis, please call or text 988 or go to your nearest emergency room. SPRAVATO® is not a substitute for emergency mental health care.
The Benefits of SPRAVATO® Therapy in Boston, Massachusetts
In the following video from Johnson & Johnson, Grace, a graphic designer with treatment-resistant depression, shares her experience with SPRAVATO® (esketamine) treatment. This video depicts Grace’s story; results may vary.
The clinical evidence behind SPRAVATO® has grown substantially in recent years. SPRAVATO® is FDA-approved, in conjunction with an oral antidepressant, for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. For Boston patients searching for an alternative when antidepressants haven’t worked, SPRAVATO® can offer a different path forward. Individual results vary.
SPRAVATO®: An Advanced Approach to Depression Treatment
SPRAVATO® works differently than traditional antidepressants, targeting the brain’s glutamate system to produce relief more rapidly than oral medications, which can take weeks to take effect. For Boston patients with treatment-resistant depression, SPRAVATO® is an important advance in care.
SPRAVATO® Therapy: A Beacon of Hope
SPRAVATO® (esketamine) was introduced in 2019 as the first FDA-approved nasal spray treatment for depression, and it has become an established part of modern psychiatric care. It is FDA-approved, in conjunction with an oral antidepressant, for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Undergoing SPRAVATO® Therapy in Boston, MA is a structured and supportive process where patients self-administer the nasal spray under direct medical supervision in our REMS-certified outpatient healthcare setting. Each session is followed by a minimum two-hour monitoring period, in a calm and private setting designed to support recovery and ensure patient safety throughout treatment.
SPRAVATO® interacts with the brain’s glutamate system, working differently than traditional antidepressants and producing relief more rapidly than oral medications for some patients. For Boston patients who have lived with depression for years, it can serve as a meaningful path forward when other treatments have not worked.
SPRAVATO® Therapy for Depression
SPRAVATO® is an important advance in the treatment of depression, specifically for adults living with treatment-resistant depression and for those with major depressive disorder experiencing acute suicidal thoughts or behaviors. For Boston patients, SPRAVATO® Therapy at Cambridge Biotherapies™ can open new possibilities for relief in cases where traditional antidepressants have not produced lasting results, offering a different mechanism and a faster timeline. Individual results vary.
Through its action on the brain’s glutamate system, SPRAVATO® may support neural connectivity, help lift mood, and reduce the severity of depressive symptoms. For many patients, this rapid-acting approach offers a chance to work toward stability, clarity, and engagement with their lives, often within a shorter timeframe than oral antidepressants. Individual results vary.
Advantages of SPRAVATO® in Treating Depression
Administered under direct medical supervision in our REMS-certified outpatient healthcare setting, SPRAVATO® offers Boston patients a different mechanism of action and a path forward when other treatments have not worked. Each treatment plan is personalized after a full psychiatric evaluation, and progress is tracked throughout your care. Individual results vary.
Testimonials
Important Safety Information
Important Safety Information — SPRAVATO (esketamine) Boxed Warnings: (1) Sedation: SPRAVATO can cause sedation and decreased alertness during and after administration. Patients must not drive or operate machinery on treatment days. (2) Dissociation: Dissociative symptoms and perceptual changes may occur during and after administration. (3) Abuse and Misuse Potential: SPRAVATO is a Schedule III controlled substance with potential for abuse and misuse. It is available only through a restricted REMS program. (4) Suicidal Thoughts and Behaviors: Monitor for worsening of depression and emergence of suicidal thoughts and behaviors, particularly in young adults. (5) Respiratory Depression: SPRAVATO may cause respiratory depression, particularly when used with central nervous system depressants. Patients should be monitored during and after each treatment session.
SPRAVATO is available only through a restricted program called the SPRAVATO REMS. Patients must receive treatment in a certified healthcare setting and be monitored by a healthcare provider for at least 2 hours after each treatment session.
Patients must not drive or operate heavy machinery on the day of their SPRAVATO treatment.
Disclosures
SPRAVATO® (esketamine) is a Schedule III controlled substance, FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. SPRAVATO® carries Boxed Warnings for sedation, dissociation, abuse and misuse, and suicidal thoughts and behaviors. Because of these risks, SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® REMS (Risk Evaluation and Mitigation Strategy). It must be administered under the direct observation of a healthcare provider in a certified healthcare setting, with patients monitored for at least two hours after each dose. SPRAVATO® must never be dispensed for home use. Cambridge Biotherapies is a SPRAVATO® REMS-certified outpatient healthcare setting.
Individual results may vary. Treatment outcomes depend on each patient’s specific condition, medical history, and response to therapy. Cambridge Biotherapies’ clinical team works with each patient to develop an individualized treatment plan.
The information on this page is for educational purposes only and is not medical advice. It is not a substitute for professional diagnosis or treatment. Always seek the guidance of your physician or qualified mental health provider with questions about a medical condition. Treatments described here are administered only after individual medical evaluation; outcomes vary by patient.
Take the First Step Now
Embark on a transformative journey with Spravato Therapy in Boston, MA. Cambridge Biotherapies is your partner in carving pathways to mental peace and holistic well-being.